Ovarian Cancer, Version 3.2012.

Nov 2012

Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D,Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW,Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA.

Source

From 1City of Hope Comprehensive Cancer Center; 2University of Alabama at Birmingham Comprehensive Cancer Center; 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 4Fox Chase Cancer Center; 5Dana-Farber/Brigham and Women's Cancer Center; 6UCSF Helen Diller Family Comprehensive Cancer Center; 7The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 8Vanderbilt-IngramCancer Center; 9The University of Texas MD Anderson Cancer Center; 10University of Washington Medical Center/SeattleCancer Care Alliance; 11Moffitt Cancer Center; 12Duke Cancer Institute; 13University of Michigan Comprehensive CancerCenter; 14Roswell Park Cancer Institute; 15Massachusetts General Hospital Cancer Center; 16UNMC Eppley CancerCenter at The Nebraska Medical Center; 17Memorial Sloan-Kettering Cancer Center; 18St. Jude Children's Research Hospital/University of Tennessee Cancer Institute; 19Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 20Stanford Cancer Institute; 21Huntsman Cancer Institute at the University of Utah; and 22National Comprehensive Cancer Network.

Abstract

These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.

JNCCN